Author:
van der Noordaa M.E.M.,van Duijnhoven F.H.,Loo C.E.,van Werkhoven E.,van de Vijver K.K.,Wiersma T.,Winter-Warnars H.A.O.,Sonke G.S.,Vrancken Peeters M.T.F.D.
Funder
Pink Ribbon, the Netherlands
Reference40 articles.
1. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial;Gianni;Lancet Oncol,2012
2. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial;von Minckwitz;Lancet Oncol,2014
3. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA);Schneeweiss;Ann Oncol : Off J Eur Soc Med Oncol,2013
4. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy;Houssami;Eur J Cancer (Oxford, England : 1990),2012
5. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet (London, England).,2014
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献